Welcome to our dedicated page for Indaptus Therapeutics news (Ticker: INDP), a resource for investors and traders seeking the latest updates and insights on Indaptus Therapeutics stock.
Indaptus Therapeutics, Inc. (Nasdaq: INDP) is a pioneering pre-clinical biotechnology company focused on developing revolutionary treatments for cancer and certain infectious diseases. By harnessing the body’s innate and adaptive immune responses, Indaptus aims to cure disease through its proprietary platform that leverages bacteria's natural ability to activate both immune pathways.
The company’s flagship candidate, Decoy20, demonstrates significant promise in pre-clinical trials, showcasing single-agent activity and durable anti-tumor responses. These trials span various cancer models, including colorectal, hepatocellular, pancreatic carcinoma, and non-Hodgkin's lymphoma. Indaptus' technology involves the use of attenuated and killed non-pathogenic Gram-negative bacteria to safely elicit broad immune responses.
In line with its commitment to transparency and education, Indaptus actively engages with the public through social media platforms. The company shares updates on its groundbreaking research, educational content about cancer immunotherapy, and behind-the-scenes insights into its scientific progress. This engagement aims to build a community passionate about medical advancements.
Indaptus has recently advanced its innovative immunotherapy for the treatment of solid metastatic tumors into Phase 1 human trials. The safety and efficacy of Decoy20 in these trials have been promising, allowing the company to progress to multi-dosing regimens. This phase aims to further explore the safety and potential benefits of repeated Decoy20 administrations.
With a strong foundation built on over a century of immunotherapy advancements, Indaptus Therapeutics is poised to make significant strides in cancer and viral infection treatment. The company’s technology has shown potential in pre-clinical models to eradicate tumors when combined with other therapies, such as anti-PD-1 checkpoint inhibitors and low-dose chemotherapy.
Indaptus’ forward-looking strategy includes ongoing research and development activities, aiming to demonstrate the utility of its technology for treating solid tumors and chronic viral infections. The company's innovative approach, coupled with a robust pre-clinical pipeline, positions it uniquely in the biotechnology landscape, making it a noteworthy entity for investors and researchers alike.
Indaptus Therapeutics, Inc. (Nasdaq: INDP) will have CEO Jeffrey A. Meckler present at the Planet MicroCap Showcase: VEGAS 2023 from April 25-27, 2023, in Las Vegas, NV. Meckler's presentation is scheduled for April 26, 2023, at 11:30 AM PT. The company focuses on developing innovative immunotherapy solutions using a patented Decoy platform aimed at activating immune responses against various cancers and chronic viral infections such as HBV and HIV.
The Decoy technology has shown promising results in pre-clinical studies, demonstrating effective tumor eradication and activation of both innate and adaptive immune pathways. Meckler will also be available for one-on-one meetings during the conference. Interested parties can register and request meetings via links in the press release.
Indaptus Therapeutics has made significant strides in its ongoing research with the Decoy platform, particularly regarding its clinical trial for Decoy 20 in solid tumors. The data presented at the AACR Annual Meeting on April 18, 2023, highlights promising results from Decoy10, an earlier generation of the Decoy platform, which demonstrated a 90% reduction in endotoxin activity and effective tumor inhibition across various models. Key findings include durable tumor regressions and the induction of immunological memory when combined with existing cancer therapies. Indaptus' Chief Scientific Officer, Michael Newman, emphasized the potential of the Decoy platform in activating multiple immune pathways, showcasing its unique ability to address high unmet needs in cancer treatment.
Indaptus Therapeutics, Inc. (Nasdaq: INDP) has received a patent allowance from the National Institute of Industrial Property of Brazil for its innovative Decoy immunotherapy platform. This patent includes a disease-agnostic composition claim, highlighting its significance in the biotechnology field. CEO Jeffrey Meckler expressed satisfaction with the global expansion of their patent portfolio and the ongoing Phase 1 trial of INDP-D101 for solid tumors. The Decoy platform aims to enhance immune response with reduced toxicity, showing promising preclinical results against various cancers and viral infections. The company is committed to strengthening its intellectual property and providing value to shareholders while progressing in clinical trials.
Indaptus Therapeutics (Nasdaq: INDP), a biotechnology company, will participate in the virtual Investor Summit Conference on March 29, 2023. Chief Executive Officer Jeffrey A. Meckler is scheduled to present a corporate overview at 10:00 AM ET. He will also be available for one-on-one meetings during the conference. The company focuses on developing innovative therapeutics leveraging its patented technology to activate immune responses safely. Indaptus aims to provide transformative solutions for various cancers and viral infections, demonstrating promising results in pre-clinical studies.
Indaptus Therapeutics (Nasdaq: INDP) announced its Q4 and fiscal year 2022 results alongside updates on its Phase 1 clinical trial of Decoy20 for solid tumors. The first patient was dosed in March 2023, showing manageable adverse events. Research and development expenses rose by 150% to approximately $6.3 million for the year, while general and administrative expenses increased by 65% to about $8.6 million. The loss per share for 2022 was $1.73, down from $1.89 in 2021. Indaptus reported cash, cash equivalents, and marketable securities of approximately $26.4 million as of December 31, 2022, expecting operational funding until Q2 2024.
Indaptus Therapeutics (Nasdaq: INDP) announced that the American Association for Cancer Research (AACR) accepted its abstract for presentation at the annual scientific conference from April 14-19, 2023, in Orlando. The poster, titled “A systemically administered killed bacteria-based multiple immune receptor agonist for pulsed anti-tumor immunotherapy,” will be presented by Michael J. Newman, Ph.D., on April 18, 2023. Indaptus focuses on innovative therapeutics leveraging a Decoy anti-tumor platform that activates immune responses safely via intravenous delivery. This technology shows promise in treating various cancers and chronic infections.
FAQ
What is the current stock price of Indaptus Therapeutics (INDP)?
What is the market cap of Indaptus Therapeutics (INDP)?
What does Indaptus Therapeutics, Inc. do?
What is Decoy20?
What makes Indaptus Therapeutics' technology unique?
What are the current projects of Indaptus Therapeutics?
What recent achievements has Indaptus Therapeutics made?
How does Indaptus Therapeutics engage with the public?
What types of cancer has Decoy20 shown promise against?
How does Indaptus’ technology work?
What is the goal of Indaptus Therapeutics?
Where can I find more updates on Indaptus Therapeutics?
